MICORNE: Miniinvasive Corneal Neurotization. A Pilot Study.

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Terminated
CT.gov ID
NCT03037450
Collaborator
(none)
1
1
1
19.7
0.1

Study Details

Study Description

Brief Summary

Neurotrophic keratitis (NK) is a degenerative disease of the cornea due to the impairment of the nasociliary branch of the ophthalmic nerve. Reduced corneal sensation lead to several corneal lesions including spontaneous ulcerations, delayed wound healing, corneal scarring, neovascularization, thinning, perforation or infection. An important and permanent visual loss of is frequently associated with the condition. NK can be congenital or acquired. Its acquired forms can be due to traumatic, infectious (herpes, zoster), neoplastic or iatrogenic causes. There is currently no specific medical treatment. Surgical reconstruction techniques of sensory neurotizations have recently been described in young patients suffering traumatic, congenital or neoplastic NK using supratrochlear nerves as the sensory donor nerves and sural nerve as healthy graft. A neurotization involves the transfer of a healthy donor nerve segment into a tissue to reestablish either motor or sensory innervation. The aim of the present study is to assess the outcomes of a novel sensory neurotization technique for the treatment of severe NK in adult patients (Stages 2 and 3 of Mackie classification). Corneal neurotizations will be performed using either ipsilateral supraorbital nerve as donor nerve (direct neurotization) or contralateral supraorbital nerve as donor nerve and a segment of the lateral antebrachial cutaneous nerve as graft. Small-size skin incisions (less than 3 centimeters) will be made in one or both eyebrow and an endoscopic device will help the surgeons to localize and dissect the supraorbital nerve. Donor nerves or graft will be sutured to the neurotrophic corneas. Adult patients with unilateral NK due to infectious, traumatic or iatrogenic causes will be included.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Miniinvasive corneal neurotization
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
1 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Miniinvasive Corneal Neurotization. A Pilot Study.
Actual Study Start Date :
Jun 1, 2017
Actual Primary Completion Date :
Jan 22, 2019
Actual Study Completion Date :
Jan 22, 2019

Arms and Interventions

Arm Intervention/Treatment
Other: Miniinvasive corneal neurotization

Procedure: Miniinvasive corneal neurotization
Neurotization of a neurotrophic cornea

Outcome Measures

Primary Outcome Measures

  1. Corneal sensation scores. [12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient older than 18.

  • NK stages 2 and 3 (Mackie's classification).

  • Non-response to maximal medical treatment (lachrymal substitution, autologous serum).

  • Postherpetic or post-zoster NK (Group 1).

  • Postoperative NK (neurosurgery and trigeminal thermocoagulation) (Group 2).

  • Posttraumatic NK (orbital trauma, ocular burn) (Group 3).

  • No ocular hypertony in both eyes.

  • Visual acuity > 20/40 on the contralateral eye.

  • Written consent of the patient.

  • Patient benefiting from national health coverage (either as a direct user or beneficiary).

Exclusion Criteria:
  • Impossibility of general anesthesia.

  • Herpetic or zoster recurrence in the 6 months prior surgery.

  • Length of NK evolution > 5 years.

  • Congenital NK.

  • Bilateral NK.

  • Other causes of NK: diabeta mellitus, amylosis, sarcoidosis, multiple sclerosis, vitamin A or B12 deficiency, Sjögren syndrome, GVH disease, topical NSAID, topical beta-blockers, history of refractive surgery.

  • Mental illness.

  • Adult with legal guardian or guardianship.

  • Pregnancy.

  • Breast-feeding.

  • Patient's unable to understand informations.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Les Hôpitaux Universitaires Strasbourg France 67000

Sponsors and Collaborators

  • University Hospital, Strasbourg, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT03037450
Other Study ID Numbers:
  • 6528
First Posted:
Jan 31, 2017
Last Update Posted:
Sep 20, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 20, 2021